Placebo + ABBV-8E12
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Supranuclear Palsy
Conditions
Progressive Supranuclear Palsy
Trial Timeline
Dec 12, 2016 → Nov 20, 2019
NCT ID
NCT02985879About Placebo + ABBV-8E12
Placebo + ABBV-8E12 is a phase 2 stage product being developed by AbbVie for Progressive Supranuclear Palsy. The current trial status is terminated. This product is registered under clinical trial identifier NCT02985879. Target conditions include Progressive Supranuclear Palsy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02985879 | Phase 2 | Terminated |
Competing Products
20 competing products in Progressive Supranuclear Palsy